- Home
- HHS vs NNVC Comparison
HHS vs NNVC Comparison
Compare HHS & NNVC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | HHS | NNVC |
|---|---|---|
| Founded | 1923 | 2005 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Advertising | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 21.2M | 21.2M |
| IPO Year | 1994 | 2008 |
Fundamental Metrics
Financial Performance| Metric | HHS | NNVC |
|---|---|---|
| Price | $2.65 | $1.53 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | 2.8K | ★ 365.1K |
| Earning Date | 05-14-2026 | 05-15-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 97.35 | 10.00 |
| EPS | ★ N/A | N/A |
| Revenue | ★ $159,570,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $2.22 | $0.85 |
| 52 Week High | $5.39 | $2.23 |
Technical Indicators
Market Signals| Indicator | HHS | NNVC |
|---|---|---|
| Relative Strength Index (RSI) | 42.81 | 58.37 |
| Support Level | $2.33 | $1.35 |
| Resistance Level | $2.89 | $1.53 |
| Average True Range (ATR) | 0.07 | 0.15 |
| MACD | -0.01 | 0.00 |
| Stochastic Oscillator | 15.63 | 50.00 |
Price Performance
Historical ComparisonAbout HHS Harte-Hanks Inc.
Harte-Hanks Inc is a customer experience company. The Company operates three business segments: Marketing Services; Customer Care; and Fulfillment & Logistics Services. The company has a geographic presence in the United States and Other countries. The majority of the revenue is earned from the United States.
About NNVC NanoViricides Inc.
Nanoviricides Inc is a nano-biopharmaceutical company that is engaged in discovering, developing, and commercializing therapeutics to advance the care of patients suffering from life-threatening viral infections. The company engaged in the application of nanomedicine technologies to the complex issues of viral diseases. It focuses its research and clinical programs on specific anti-viral therapeutics and is seeking to add to its existing portfolio of products through its internal discovery and clinical development programs and through in-licensing.